Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06299111 · ClinicalTrials.gov registry record · Phase 2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
A Phase 2 study of Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT06299111 is a Phase 2 study of Venous Thromboembolism that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 195 participants, below the 6,292-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06299111, a Phase 2 study of Venous Thromboembolism, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7508
- DRUG REGN9933
Study Locations (20)
Other
- Sveta Sofia Hospital - Sofia
- Hadassah University Medical Center - Jerusalem
- Lanadio Medical Center - Netanya
- Rabin Medical Center - Petah Tikva
- Sheba Medical Center - Ramat Gan
- Tel Aviv Sourasky Medical Center - Tel Aviv
- Arensia Research Clinic - Bucharest
- Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca - Cluj-Napoca
Ontario
- Juravinski Hospital - Hamilton
- London Health Sciences Centre - London
- Lakeridge Health - Oshawa
- University Health Network - Toronto
New York
- Mount Sinai Medical Center - New York
- Memorial Sloan Kettering - New York
California
- Cedars-Sinai Medical Center - Los Angeles
Florida
- Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Henry Ford Health System - Detroit
Jerusalem
- Shaare Zedek Medical Center - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06299111
The ClinicalTrials.gov registry entry for NCT06299111 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,292-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (97% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06299111 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Ontario, New York.
Frequently Asked Questions
What is clinical trial NCT06299111 about?
NCT06299111 is a clinical study titled "A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)". This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing veno...
What is the current status of trial NCT06299111?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2024-09-20. Estimated completion is 2026-06-01.
What conditions does trial NCT06299111 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT06299111?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG), REGN9933 (DRUG).
Who is sponsoring clinical trial NCT06299111?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06299111 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
RECRUITING · Phase 2
-
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
COMPLETED · Phase 2
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.